within Pharmacolibrary.Drugs.ATC.M;

model M01AA03
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 6.666666666666667e-06,
    adminDuration  = 600,
    adminMass      = 400 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0087,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008333333333333333,
    Tlag           = 600,            
    Vdp             = 0.0031,
    k12             = 0.41,
    k21             = 0.41
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>M01AA03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Oxyphenbutazone is a nonsteroidal anti-inflammatory drug (NSAID) of the pyrazolidinedione class, formerly used in the treatment of rheumatoid arthritis and other inflammatory conditions. Due to safety concerns, particularly risk of severe adverse hematological reactions such as agranulocytosis, the drug is no longer approved or widely used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are reported for healthy adult volunteers (sex not specified) following oral administration.</p><h4>References</h4><ol><li><p>Aarbakke, J (1978). Clinical pharmacokinetics of phenylbutazone. <i>Clinical pharmacokinetics</i> 3(5) 369–380. DOI:<a href=\"https://doi.org/10.2165/00003088-197803050-00003\">10.2165/00003088-197803050-00003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/359213/\">https://pubmed.ncbi.nlm.nih.gov/359213</a></p></li><li><p>Jaraiz, V, Rodriguez, C, San Andres, MD, Gonzalez, F, &amp; San Andres, MI (1999). Pharmacokinetics and bioequivalence of two suxibuzone oral dosage forms in horses. <i>Journal of veterinary pharmacology and therapeutics</i> 22(4) 247–254. DOI:<a href=\"https://doi.org/10.1046/j.1365-2885.1999.00219.x\">10.1046/j.1365-2885.1999.00219.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10499236/\">https://pubmed.ncbi.nlm.nih.gov/10499236</a></p></li><li><p>Verbeeck, RK (1990). Pharmacokinetic drug interactions with nonsteroidal anti-inflammatory drugs. <i>Clinical pharmacokinetics</i> 19(1) 44–66. DOI:<a href=\"https://doi.org/10.2165/00003088-199019010-00004\">10.2165/00003088-199019010-00004</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2199127/\">https://pubmed.ncbi.nlm.nih.gov/2199127</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end M01AA03;
